title: Uveitis following intravitreal bevacizumab: a non-infectious cluster.
abstract: OBJECTIVE
  In this retrospective case series, the authors report seven cases of bevacizumab-related uveitis that occurred within a 4-month period.
  
  
  METHODS
  Seven eyes of six patients developed non-infectious uveitis following bevacizumab intravitreal injections in a cohort of 978 consecutive bevacizumab injections.
  
  
  RESULTS
  The mean age of patients was 74.6 years (range: 26 to 92). All patients developed symptom onset within 1 day of injection. Shared signs and symptoms included corneal edema, anterior chamber and vitreous cell, conjunctival injection, ocular pain, and lack of hypopyon. In all patients, visual acuity returned to within one line of baseline acuity. All seven eyes had been previously injected with bevacizumab, with a mean number of antecedent injections of 6.1 (range: 3 to 12).
  
  
  CONCLUSIONS
  A cluster of sterile bevacizumab-related uveitic reactions was described in this case series. Acute onset of symptoms, absence of hypopyon, a predominant anterior segment reaction, and prompt improvement on topical steroid therapy are useful clinical features distinguishing this uveitic syndrome from infectious endophthalmitis.
authors.affiliation: Vitreoretinal Service, Department of Ophthalmology & Visual Sciences, Carver School of Medicine, The University of Iowa, Iowa City, Iowa, USA. christinemnichols@hotmail.com
authors.forename: Christine N
authors.initials: CN
authors.lastname: Kay
authors.forename: Ryan M
authors.initials: RM
authors.lastname: Tarantola
authors.forename: Karen M
authors.initials: KM
authors.lastname: Gehrs
authors.forename: James C
authors.initials: JC
authors.lastname: Folk
authors.forename: Vinit B
authors.initials: VB
authors.lastname: Mahajan
authors.forename: H Culver
authors.initials: HC
authors.lastname: Boldt
authors.forename: Nasreen A
authors.initials: NA
authors.lastname: Syed
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Russell
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D058449:Intravitreal Injections; D008875:Middle Aged; D012189:Retrospective Studies; D014606:Uveitis, Anterior / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab